Elite Pharmaceuticals Inc
OTC:ELTP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Elite Pharmaceuticals Inc
Other Long-Term Assets
Elite Pharmaceuticals Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elite Pharmaceuticals Inc
OTC:ELTP
|
Other Long-Term Assets
$10.8m
|
CAGR 3-Years
61%
|
CAGR 5-Years
93%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Long-Term Assets
$19.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Long-Term Assets
$8.2B
|
CAGR 3-Years
42%
|
CAGR 5-Years
20%
|
CAGR 10-Years
8%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Long-Term Assets
$19.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
28%
|
CAGR 10-Years
14%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Long-Term Assets
$17.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Long-Term Assets
$17B
|
CAGR 3-Years
33%
|
CAGR 5-Years
22%
|
CAGR 10-Years
23%
|
|
Elite Pharmaceuticals Inc
Glance View
Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. The company is headquartered in Northvale, New Jersey and currently employs 43 full-time employees. The company went IPO on 2014-02-20. The firm is principally engaged in the development and manufacture of oral, controlled-release products. The firm develops and manufactures generic products, products using controlled-release drug technology, products utilizing abuse deterrent technologies, and it develops and markets (either on its own or by license to other companies) generic controlled-release and abuse deterrent pharmaceutical products. Its segments include Abbreviated New Drug Applications (ANDA) for generic products and New Drug Applications (NDA) for branded products. Elite owns, licenses and contract manufactures products, including Phentermine HCl 37.5mg tablets , Phendimetrazine Tartrate 35mg tablets, Naltrexone HCl 50mg tablets, Isradipine 2.5mg and 5mg capsules, Oxycodone HCl Immediate Release 5mg, 10mg, 15mg, 20mg and 30mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, among others.
See Also
What is Elite Pharmaceuticals Inc's Other Long-Term Assets?
Other Long-Term Assets
10.8m
USD
Based on the financial report for Dec 31, 2025, Elite Pharmaceuticals Inc's Other Long-Term Assets amounts to 10.8m USD.
What is Elite Pharmaceuticals Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
93%
Over the last year, the Other Long-Term Assets growth was -49%. The average annual Other Long-Term Assets growth rates for Elite Pharmaceuticals Inc have been 61% over the past three years , 93% over the past five years .
